[smcn/Fotolia] Illumina is committing $100 million over 10 years to a new venture capital firm whose investment priorities will be in line with the company’s vision. Illumina biotechnology company US has pledged $100 million over a 10 years period to a new, venture capital ( Illumina Ventures ) firm known as Illumina Ventures . This new organisation will share the same values and vision for the future as its parent company, although it will operate independently. Nevertheless, a condition of this investment is Illumina becoming the majority limited partner in the new firm's first fund. This new VC fund will invest in incubator-style companies that are working on projects dedicated to unlocking the potential of the human genome. Examples of innovative projects include cutting-edge nucleic acid sequencing techniques, products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing. This initiative is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups.
Illumina biotechnology company US has pledged $100 million over a 10 years period to a new, venture capital ( Illumina Ventures ) firm known as Illumina Ventures . This new organisation will share the same values and vision for the future as its parent company, although it will operate independently. Nevertheless, a condition of this investment is Illumina becoming the majority limited partner in the new firm's first fund. This new VC fund will invest in incubator-style companies that are working on projects dedicated to unlocking the potential of the human genome. Examples of innovative projects include cutting-edge nucleic acid sequencing techniques, products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing. This initiative is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups.